3.0 T neuroimaging: technical considerations and clinical applications

Neuroimaging Clin N Am. 2006 May;16(2):217-28, ix. doi: 10.1016/j.nic.2006.02.007.


Since approval by the US Food and Drug Administration (FDA) in 2000, human MR imaging at field strength up to 4.0 T in clinical practice and up to 8.0 T on research systems has become available. Although human MR imaging at field strengths greater than 1.5 T was performed even before 1999 on research systems, the FDA approval for clinical use and the advent of actively shielded magnets marked a new trend for MR vendors and users. Because of the potential technical benefits when moving from 1.5 T to 3.0 T, the number of 3.0 T installations is increasing continuously worldwide. This article reviews the benefits, challenges, and the current knowledge of 3.0 T whole body MR imaging and summarizes its clinical applications.

Publication types

  • Review

MeSH terms

  • Adult
  • Brain / pathology*
  • Contrast Media
  • Diffusion Magnetic Resonance Imaging / methods
  • Female
  • Humans
  • Magnetic Resonance Angiography / methods
  • Magnetic Resonance Imaging* / methods
  • Magnetic Resonance Spectroscopy / methods
  • Magnetics
  • Male
  • Middle Aged
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Spin Labels
  • Time Factors


  • Contrast Media
  • Spin Labels